Hidradenitis Supparativa (HS)

Hidradenitis Suppurativa: (Oral Therapy):C5a Receptor Inhibitor: Avacopan (CCX168), Placebo

Do you meet these requirements?

  • Male or female, aged 18 years or older
  • Clinical diagnosis of HS (Hurley Stage II or III) confirmed by a dermatologist, for at least 6 months prior to screening
  • HS lesions are present in at least 2 distinct anatomic areas
  • Inadequate or loss of response to a systemic course of antibiotics of at least 90 days (or demonstrated intolerance to or had a contraindication to antibiotics to treat HS)

13 visits during a 50 week period; Travel reimbursement: TBD

The Derm Group Location: Verona, NJ

For more information, call 1-(973)571-2121 ext. 5920 or email ctrials@thedermgroup.com

Or Contact The Verona Research Hotline 1-201-478-9119 Call or Text

The medication, procedures, and all study visits are provided without financial costs to you.  No insurance coverage is required.  All enrolled participants will be compensated for their time and travel at the completion of the study.

Back to Top